In this Drug Channels Institute guest post, “Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different,” PANTHERx’s Chief Commercial & Clinical Officer, Dr. Richard Faris, details why precision, partnership, and patient focus are critical to successful rare disease market entries. He also explores how “launch levers” such as early ecosystem collaboration, aligned data and technology, and a strong payer value story can help manufacturers and their pharmacy partners deliver innovative rare treatments to eligible patients quickly after FDA approval.
